Funding for this research was provided by:
Defense Advanced Research Projects Agency (HR0011-17-2-0047)
Tata Institute for genetics and Society University of California, Irvine Malaria Initiative
Received: 19 May 2020
Accepted: 13 October 2020
First Online: 3 November 2020
: V.M.G. and E.B. have an equity interest in Synbal, Inc. and Agragene, Inc. companies that may potentially benefit from the research results, and serve on both companies’ Scientific Advisory Board and on the Board of Directors of Synbal, Inc. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict-of-interest policies. Remaining authors declare no competing interests.